Table 3.

Clinical variables associated with seroconversion 1 month following second vaccine

	Post second vaccine OR (95% CI)	P value
RBD seroconversion
Sex
Male	Ref	1.0
Female	1.0 (0.21 to 4.71)
Age (years)
>65	Ref	0.002
≤65	7.4 (2.04 to 27.06)
IMID
IBD	Ref	<0.001
IA	0.2 (0.02 to 2.65)
SARD	0.05 (0.003 to 0.79)
MS	0.009 (0.001 to 0.13)
Immune therapy
None	Ref	0.004
Other immunomodulator	NA
Immunosuppressant	0.03 (0.002 to 0.33)
Biologic	0.02 (0.002 to 0.16)
S1 seroconversion
Sex
Male	Ref	0.85
Female	1.1 (0.29 to 4.52)
Age (years)
>65	Ref	0.02
≤65	3.9 (1.29 to 11.62)
IMID
IBD	Ref	<0.001
RA	0.5 (0.07 to 3.02)
SARD	0.1 (0.01 to 0.91)
MS	0.03 (0.003 to 0.20)
Immune therapy
None	Ref	0.01
Other immunomodulator	NA
Immunosuppressant	0.06 (0.006 to 0.51)
Biologic	0.04 (0.007 to 0.27)

Biologics: tumour necrosis factor antagonists, abatacept, tocilizumab, tofacitinib, upadacitinib, ustekinumab, apremilast, rituximab, anakinra and B cell-targeted therapies (rituximab, belimumab, ocrelizumab); immunosuppressants: methotrexate, leflunomide and mycophenolate; immunomodulators: hydroxychloroquine and sulfasalazine.

IA, inflammatory arthritis; IBD, inflammatory bowel disease; IMID, immune-mediated inflammatory disease; MS, multiple sclerosis; NA, not able to compute; RBD, receptor binding domain; Ref, reference category; S1, spike protein; SARD, systemic autoimmune rheumatic disease.